The recommendations of the 2019 European League Against Rheumatism (EULAR) stated that the efficacies of anti-interleukin (IL)-6 receptor antibody (aIL-6R; tocilizumab and sarilumab), cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig; abatacept) and Janus kinase inhibitors (JAKi) such as baricitinib (BAR; a JAK1 and JAK2 inhibitor) and tofacitinib (TOF; a JAK1 and JAK3 inhibitor) are considered equivalent to those of tumor necrosis factor inhibitors (TNFi) in both Phase II and Phase III treatments of rheumatoid arthritis (RA)1. The gene discussed is JAK3; the disease is rheumatoid arthritis.